Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Enlivex Therapeutics Ltd
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
July 23, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
June 24, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
June 20, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
June 17, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
June 03, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
May 29, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
May 28, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
April 29, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
April 22, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
April 16, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
April 11, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
April 11, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
February 07, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
January 17, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
December 20, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
September 11, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
August 02, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
July 31, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
June 26, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex to Present at the 2023 Jefferies Healthcare Conference
June 06, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
May 31, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy
May 08, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
April 19, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Appoints Andrew Singer to its Board of Directors
April 17, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
April 04, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors
April 03, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
March 20, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial
February 23, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS
February 15, 2023
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tickers
ENLV
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.